Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

ClinicalTrials.gov ID: NCT05370521

Public ClinicalTrials.gov record NCT05370521. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens

Study identification

NCT ID
NCT05370521
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Spruce Biosciences
Industry
Enrollment
27 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Tildacerfont Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 40 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 14, 2022
Primary completion
Aug 2, 2023
Completion
Aug 30, 2023
Last update posted
Oct 8, 2025

2022 – 2023

United States locations

U.S. sites
21
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
Spruce Study Site Sacramento California 95817
Spruce Study Site San Francisco California 94158
Spruce Study Site New Haven Connecticut 06519
Spruce Study Site Clearwater Florida 33759
Spruce Study Site Lake Worth Florida 33461
Spruce Study Site Miami Florida 33173
Spruce Study Site Winter Park Florida 32792
Spruce Study Site Idaho Falls Idaho 83404
Spruce Study Site Wichita Kansas 67226
Spruce Study Site Boston Massachusetts 02115
Spruce Study Site Fall River Massachusetts 02720
Spruce Study Site Southfield Michigan 48034
Spruce Study Site Williamsville New York 14221
Spruce Study Site Raleigh North Carolina 27612
Spruce Study Site Cincinnati Ohio 45219
Spruce Study Site Cleveland Ohio 44106
Spruce Study Site Philadelphia Pennsylvania 19104
Spruce Study Site Bedford Texas 76022
Spruce Study Site Houston Texas 77024
Spruce Study Site Houston Texas 77030
Spruce Study Site Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05370521, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 8, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05370521 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →